Clinical Trial Update: Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas [Phase 2]

View source ↗

Summary

Phase 2 study of bimagrumab (BYM338) for cancer cachexia causing unintentional weight loss in patients with lung or pancreatic cancer has completed and results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer Cachexia

Drugs mentioned

• Bimagrumab (bimagrumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cachexia | Phase 2 | Status: COMPLETED | Results posted: 2015-05-13